China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market